发明申请
US20090311266A1 Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
审中-公开
内皮素信号通路的抑制剂和alphavbeta3整合素受体拮抗剂联合治疗
- 专利标题： Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
- 专利标题（中）： 内皮素信号通路的抑制剂和alphavbeta3整合素受体拮抗剂联合治疗
-
申请号： US12433295申请日： 2009-04-30
-
公开(公告)号： US20090311266A1公开(公告)日： 2009-12-17
- 发明人: Wilhelm Amberg , Andreas Kling , Wilfried Hornberger
- 申请人： Wilhelm Amberg , Andreas Kling , Wilfried Hornberger
- 申请人地址： DE Ludwigshafen
- 专利权人： BASF AKTIENGESELLSCHAFT
- 当前专利权人： BASF AKTIENGESELLSCHAFT
- 当前专利权人地址： DE Ludwigshafen
- 优先权： DE199482691 19991006; DE199629986 19991224; DE100275141 20000606; DE100285759 20000614; DE100399983 20000811
- 主分类号： A61K39/395
- IPC分类号： A61K39/395
摘要：
The invention relates to the use of an endothelin blocker in combination with an αvβ3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an αvβ3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.
信息查询
